Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial

Alassane Dicko, Sidy O Toure, Mariam Traore, Issaka Sagara, Ousmane B Toure, Mahamadou S Sissoko, Alpha T Diallo, Christophe Rogier, Roger Salomon, Alexandra de Sousa, Ogobara K Doumbo, Alassane Dicko, Sidy O Toure, Mariam Traore, Issaka Sagara, Ousmane B Toure, Mahamadou S Sissoko, Alpha T Diallo, Christophe Rogier, Roger Salomon, Alexandra de Sousa, Ogobara K Doumbo

Abstract

Background: Even though the efficacy of Intermittent Preventive Treatment in infants (IPTi) with Sulfadoxine-Pyrimethamine (SP) against clinical disease and the absence of its interaction with routine vaccines of the Expanded Immunization Programme (EPI) have been established, there are still some concerns regarding the addition of IPTi, which may increase the work burden and disrupt the routine EPI services especially in Africa where the target immunization coverage remains to be met. However IPTi may also increase the adherence of the community to EPI services and improve EPI coverage, once the benefice of strategy is perceived.

Methods: To assess the impact of IPTi implementation on the coverage of EPI vaccines, 22 health areas of the district of Kolokani were randomized at a 1:1 ratio to either receive IPTi-SP or to serve as a control. The EPI vaccines coverage was assessed using cross-sectional surveys at baseline in November 2006 and after one year of IPTi pilot-implementation in December 2007.

Results: At baseline, the proportion of children of 9-23 months who were completely vaccinated (defined as children who received BGG, 3 doses of DTP/Polio, measles and yellow fever vaccines) was 36.7% (95% CI 25.3% -48.0%). After one year of implementation of IPTi-SP using routine health services, the proportion of children completely vaccinated rose to 53.8% in the non intervention zone and 69.5% in the IPTi intervention zone (P <0.001).The proportion of children in the target age groups who received IPTi with each of the 3 vaccinations DTP2, DTP3 and Measles, were 89.2% (95% CI 85.9%-92.0%), 91.0% (95% CI 87.6% -93.7%) and 77.4% (95% CI 70.7%-83.2%) respectively. The corresponding figures in non intervention zone were 2.3% (95% CI 0.9% -4.7%), 2.6% (95% CI 1.0% -5.6%) and 1.7% (95% CI 0.4% - 4.9%).

Conclusion: This study shows that high coverage of the IPTi can be obtained when the strategy is implemented using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the district of Kolokani, Mali.

Trial registration: ClinicalTrials.gov NCT00766662.

References

    1. Egan A, Crawley J, Schellenberg D. IPTi Consortium. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health. 2005;10(9):815–7. doi: 10.1111/j.1365-3156.2005.01474.x.
    1. Aponte JJ, Schellenberg D, Egan A. et al.Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009;374(9700):1533–42. doi: 10.1016/S0140-6736(09)61258-7.
    1. Gosling RD, Gesase S, Mosha JF. et al.Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1521–32. doi: 10.1016/S0140-6736(09)60997-1.
    1. Hutton G, Schellenberg D, Tediosi F. et al.Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ. 2009;87(2):123–9. doi: 10.2471/BLT.08.051961.
    1. Pool R, Mushi A, Schellenberg JA, Mrisho M. et al.The acceptability of intermittent preventive treatmentof malaria in infants (IPTi) delivered through the expanded programme of immunization in southern Tanzania. Malar J. 2008;7:213.
    1. Gysels M, Pell C, Mathanga DP. et al.Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J. 2009;8:191. doi: 10.1186/1475-2875-8-191.
    1. Conteh L, Sicuri E, Manzi F. et al.The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One. 2010;5(6):e10313. doi: 10.1371/journal.pone.0010313.
    1. Schellenberg D, Menendez C, Kahigwa E. et al.Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001;357:1471–7. doi: 10.1016/S0140-6736(00)04643-2.
    1. Macete E, Aide P, Aponte JJ. et al.Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo- controlled trial. J Infect Dis. 2006;194:276–85. doi: 10.1086/505431.
    1. World Health Organisation. Interim report on IPTi with SP. WHO Advisory Committee on Serological responses to EPI vaccines in Infants receiving IPTi. (Internal Report) 2006.
    1. ter Kuile FO, Steketee RW. Intermittent preventive treatment in infants--adjusting expectations and seeing opportunity. J Infect Dis. 2006;194(3):269–72. doi: 10.1086/505434.
    1. de Sousa A, Rabarijaona LP, Tenkorang O, Pharmacovigilance of malaria Intermittent Preventive Treatment in infants coupled with routine immunizations in six African countries. J Infect Dis. in press .
    1. WHO Policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxine pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa.
    1. Munday S. Review of intermittent preventive treatment for malaria in infants and children. J Paediatr Child Health. 2007;43(6):424–8. doi: 10.1111/j.1440-1754.2007.01105.x.
    1. de Sousa A, Rabarijaona LP, Ndiaye JL, Acceptability of coupling Intermittent Preventive Treatment in infants with the Expanded Program on Immunization in three francophone countries in Africa. Trop Med Int Health. in press .
    1. Ministère de la Santé; République du Mali. Annuaire Système Local d'Information Sanitaire (SLIS) 2006. DNS - N'Tominkorobougou. 2007.
    1. Coulibaly D, Diallo DA, Thera MA. et al.Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg. 2002;67(6):604–10.
    1. Dicko A, Sagara I, Diemert D. et al.Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. Am J Trop Med Hyg. 2007;77(6):1028–33.
    1. Dicko A, Sagara I, Sissoko MS. et al.Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J. 2008;7:123. doi: 10.1186/1475-2875-7-123.
    1. Tekete M, Djimdé AA, Beavogui AH. et al.Efficacy of chloroquine, amodiaquine and sulphadoxine pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malar J. 2009;8:34. doi: 10.1186/1475-2875-8-34.
    1. Dicko A, Sagara I, Djimdé AA. et al.Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J. 2010;9:9. doi: 10.1186/1475-2875-9-9.
    1. Dicko A, Diallo AI, Tembine I. et al.Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011;8(2):e1000407. doi: 10.1371/journal.pmed.1000407.
    1. Enquête Démographique et de Santé (EDSM-III), Mali.
    1. Enquête Démographique et de Santé (EDSM-IV), Mali.
    1. WHO Immunization coverage cluster survey reference manual.
    1. Odusanya OO, Alufohai EF, Meurice FP, Ahonkhai VI. Determinants of vaccination coverage in rural Nigeria. BMC Public Health. 2008;8:381. doi: 10.1186/1471-2458-8-381.
    1. Rahman M, Islam MA, Mahalanabis D. Mother's knowledge about vaccine preventable diseases and immunization coverage in a population with high rate of illiteracy. J Trop Pediatr. 1995;41:376–8.
    1. Chandramohan D, Owusu-Agyei S, Carneiro I. et al.Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727–33. doi: 10.1136/bmj.331.7519.727.
    1. World Health Organization. World health report 2006: working together for health. Geneva;
    1. Manzi F, Schellenberg J, Hamis Y. et al.Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health stratetegy. Trans R Soc Trop Med Hyg. 2009;103(1):79–86. doi: 10.1016/j.trstmh.2008.08.014.
    1. de Sousa A, Salama P, Chopra M. Implementing intermittent preventive treatment in infants. Lancet. 2010;375(9709):121.
    1. World Health Organization. State of the World's Vaccines and Immunization 2002. World Health Organization; Geneva; 2002.
    1. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I. Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop Med Int Health. 2007;12(6):743–50. doi: 10.1111/j.1365-3156.2007.01844.x.
    1. Institute of Medicine. Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants. Letter Report.
    1. Report of the Technical Expert Group (TEG) Meeting on Intermittent Preventive Therapy in Infancy (IPTi) Geneva 8-10 October 2007.
    1. Report of the Technical Expert Group (TEG) Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy, 23-24 April 2009 - WHO\HQ, Geneva, Switzerland.
    1. Koumaré AK, Traore D, Haidara F. et al.Evaluation of immunization coverage within the Expanded Program on Immunization in Kita Circle, Mali: a cross-sectional survey. BMC Int Health Hum Rights. 2009;9(Suppl 1):S13. doi: 10.1186/1472-698X-9-S1-S13.
    1. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions and recommendations. Weekly epidemiological record. 2009;84(50):517–532.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner